EU regulators recommend approving Gilead's new hepatitis C drug
May 27, 2016 at 07:26 AM EDT
May 27 (Reuters) - Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines Agency.
